| Identification | Back Directory | [Name]
3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID | [CAS]
34576-94-8 | [Synonyms]
BT2
3,6-dichloro-2-benzothiophenecarboxylic acid
3,6-dichlorobenzothiophene-2-carboxylic acid
3,6-Dichloro-1-benzothiophene-2-carboxylicaci
Benzo[b]thiophene-2-carboxylic acid, 3,6-dichloro-
JR-6478, 3,6-Dichlorobenzo[b]thiophene-2-carboxylic acid, 97% | [Molecular Formula]
C9H4Cl2O2S | [MDL Number]
MFCD00781745 | [MOL File]
34576-94-8.mol | [Molecular Weight]
247.1 |
| Chemical Properties | Back Directory | [Boiling point ]
426.4±40.0 °C(Predicted) | [density ]
1.653±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Soluble in DMSO (up to at least 20 mg/ml) | [form ]
solid | [pka]
2.09±0.30(Predicted) | [color ]
Off-white | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
3,6-dichloro-benzo[b]thiophene-2-Carboxylic acid is an inhibitor of myeloid cell leukemia 1 (Mcl-1) with a Ki value of 59 μM for binding of FITC-Mcl-1-BH2 peptide binding to Mcl-1.1 It has been used as a building block in the synthesis of inhibitors of Mcl-1, the toll-like receptor 3/double-stranded RNA (TLR3/dsRNA) complex, and D-amino acid oxidase (DAO).1,2,3 | [Uses]
BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC)[1]. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM[2]. | [in vivo]
BT2 (20 mg/kg/day; intraperitoneal injection; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 treatment reduces the protein levels of BDK in kidneys and heart[1]. | Animal Model: | C57BL/6J male mice (8-10-week-old)[1] | | Dosage: | 20 mg/kg/day | | Administration: | Intraperitoneal injection; daily; for 1 week | | Result: | BCKDC activity was robustly (12.3-fold) enhanced in the heart compared with the vehicle-treated animals. Less activation was obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The protein levels of BDK in kidneys and heart were reduced to averages of 39 and 24%, respectively.
|
| [IC 50]
BDK: 3.19 μM (IC50); Mcl-1: 59 μM (Ki) | [storage]
Store at -20°C | [References]
1) Tso et al. (2014), Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase; J. Biol. Chem., 289 20583
2) Friberg et al. (2013), Discovery of potent myeloid cell leukemia (Mcl 1) inhibitors using fragment based methods and structure based design; J. Med. Chem. 56 15 |
|
|